Abstract CT102: Rates and impact of combination immunotherapy with tumor treating fields in a glioma cohort

TY - JOUR

T1 - Abstract CT102: Rates and impact of combination immunotherapy with tumor treating fields in a glioma cohort

AU - Odia, Yazmin

AU - Schulte, Jessica

AU - Iwamoto, Fabio

N1 - Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Tumor-treating fields (TTF) are approved for use in patients with glioblastomas at recurrence (2011) or adjuvant setting (2016) due to survival benefit in various trials. Since 12/2012, 46 patients were treated with TTF for de novo or recurrent gliomas at Columbia University.

PY - 2017/7/1

Y1 - 2017/7/1

UR - http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2017-CT102

U2 - 10.1158/1538-7445.AM2017-CT102

DO - 10.1158/1538-7445.AM2017-CT102

M3 - Article

VL - 77

JO - Cancer research

JF - Cancer research

ER -